24/7 Market News Snapshot 24 June, 2025 – DSS, Inc. (NYSE:DSS)

June 24, 2025

DENVER, Colo., 24 June, 2025 (www.247marketnews.com) – (NYSE:DSS) are discussed in this article.
DSS, Inc. (DSS) is currently navigating a challenging market environment, with shares trading at $0.905 in pre-market, marking a decline of approximately 4.74% from the previous close of $0.950. This downturn occurs amid significant trading activity, with a volume of 2.08 million shares being exchanged, indicating increased selling pressure. The persistent negative momentum suggests a waning interest from buyers, raising concerns over potential further declines, as investors closely monitor key support levels which, if breached, could heighten market volatility. Caution is warranted as external factors and overall market sentiment may influence the price trajectory of DSS.

In parallel to these market developments, DSS, through its subsidiary Impact BioMedical Inc., has made substantial strides in its corporate strategy by entering into a merger agreement with the global pharmaceutical entity, Dr. Ashleys Limited. This agreement paves the way for Dr. Ashleys to acquire Impact through a reverse merger, culminating in the establishment of a new publicly traded company, “PubCo,” on the NYSE American.

This merger signifies a transformative step for both Impact and DSS, reinforcing the company’s aim to unlock significant value within its diverse asset portfolio. The collaboration between Dr. Ashleys’ robust manufacturing expertise and Impact’s innovative R&D will streamline pathways towards creating groundbreaking biopharmaceutical therapies.

Strategically, the merger includes several key actions, such as the conversion of Impact’s Series A Preferred Stock and the exercise of debt-to-equity rights by DSS, enhancing its strategic role within the newly formed PubCo. Jason Grady, CEO of DSS, has emphasized the transaction’s potential to drive value for shareholders, marking a pivotal moment in the company’s growth trajectory. With unanimous approval from both boards and pending regulatory and shareholder endorsements, this merger promises an exciting future for DSS and its stakeholders.

Related news for (DSS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.